Skip to main content

Margaret Bynoe, PhD

Dr. Margaret Bynoe

Department of Microbiology and Immunology

Professor of Immunology
Director of Graduate Studies, 
    Field of Immunology and Infectious Disease

Department of Microbiology and Immunology
Cornell University College of Veterinary Medicine
C5 165 VMC
Ithaca, NY 14853

Office: 607.253.4023

Research Interest

The focus of the lab is to understand how the immune system works and to elucidate the cellular and molecular basis of immune defects/dysfunctions that manifest in autoimmune diseases {such as MS and inflammatory bowel diseases (IBD)} or failure of the immune system to eradicate cancer. Armed with knowledge gained from these studies, we then aim to develop immune-based therapeutic approaches to mitigate or eliminate these manifestations. We therefore focus on immune regulation at systemic and mucosal sites (including the skin and the gut) and the central nervous system. To accomplish our goals, several areas of study are ongoing in the lab.


BS (Long Island University)
PhD (Albert Einstein College of Medicine)
Postdoctoral Associate/Associate Research Scientist (Yale)

Biography/Professional Experience

Dr. Margaret Bynoe, an Associate Professor in the Department of Immunology and Infectious Diseases, received her Bachelor of Science degree in Biology from Long Island University in 1991. She received her PhD from Albert Einstein College of Medicine in 1999 where she studied the molecular basis of steroid hormones in the development of the autoimmune disease, systemic lupus erythematosus. She received her postdoctoral training in the laboratory of the late Charles A Janeway, Jr. where she studied the immunological bases of Type1 Diabetes and multiple sclerosis (MS) and later became an Associate Research Scientist at Yale University School of Medicine. Her major source of funding is the NIH and also recently the National Multiple Sclerosis Society.


Torres L, Robinson SA, Kim DG, Yan A, Cleland TA, Bynoe MS. Toxoplasma gondii alters NMDAR signaling and induces signs of Alzheimer's disease in wild-type, C57BL/6 mice. J Neuroinflammation. 2018 Feb 23;15(1):57. doi: 10.1186/s12974-018-1086-8. PMID:29471842

Kim DG, Bynoe MS. A2A adenosine receptor modulates drug efflux transporter P-glycoprotein at the blood-brain barrier. J Clin Invest. 2016 May 2;126(5):1717-33. doi: 10.1172/JCI76207. Epub 2016 Apr 4. PMID:27043281

Kim DG, Krenz A, Toussaint LE, Maurer KJ, Robinson SA, Yan A, Torres L, Bynoe MS. Non-alcoholic fatty liver disease induces signs of Alzheimer's disease (AD) in wild-type mice and accelerates pathological signs of AD in an AD model. J Neuroinflammation. 2016 Jan 5;13:1. doi: 10.1186/s12974-015-0467-5. PMID: 26728181

Bynoe MS, Viret C, Yan A, Kim DG. Adenosine receptor signaling: a key to opening the blood-brain door. Fluids Barriers CNS. 2015 Sep 2;12:20. doi: 10.1186/s12987-015-0017-7. Review. PMID:26330053

Mahamed DA, Toussaint LE, Bynoe MS. CD73-generated adenosine is critical for immune regulation during Toxoplasma gondii infection. Infect Immun. 2015 Feb;83(2):721-9. doi: 10.1128/IAI.02536-14. Epub 2014 Dec 1.

Kim DG, Bynoe MS. A2A Adenosine Receptor Regulates the Human Blood-Brain Barrier Permeability. Mol Neurobiol. 2015 Aug;52(1):664-78. doi: 10.1007/s12035-014-8879-2. Epub 2014 Sep 28. PMID:25262373

Awards and Honors

Professional/Academic Affiliations

Dr. Bynoe is a member of the following Graduate Fields:

Share this: